Scidev Ltd
ASX:SDV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Scidev Ltd
ASX:SDV
|
AU |
|
Beijing LongRuan Technologies Inc
SSE:688078
|
CN |
|
Medirom Healthcare Technologies Inc
NASDAQ:MRM
|
JP |
|
Allbirds Inc
NASDAQ:BIRD
|
US |
|
Z
|
ZheJiang RIFA Precision Machinery Co Ltd
SZSE:002520
|
CN |
|
M
|
Merck KGaA
OTC:MKGAF
|
DE |
|
I
|
InterCard Informationssysteme AG
F:II8
|
DE |
|
China Resources Mixc Lifestyle Services Ltd
HKEX:1209
|
CN |
|
L
|
Laguna Resorts and Hotels PCL
SET:LRH
|
TH |
|
B
|
Belgravia Hartford Capital Inc
CNSX:BLGV
|
CA |
|
L
|
Luxchem Corporation Bhd
KLSE:LUXCHEM
|
MY |
|
K
|
Kawagishi Bridge Works Co Ltd
TSE:5921
|
JP |
|
Kuang-Chi Technologies Co Ltd
SZSE:002625
|
CN |
|
EZCORP Inc
NASDAQ:EZPW
|
US |
|
E
|
Eletromidia SA
BOVESPA:ELMD3
|
BR |
|
T
|
Tyme Technologies Inc
F:RFL
|
US |
|
STINAG Stuttgart Invest AG
F:STG
|
DE |
|
Elgi Equipments Ltd
NSE:ELGIEQUIP
|
IN |
|
A
|
Ananti Inc
KOSDAQ:025980
|
KR |
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
IN |
|
Shandong Gold Mining Co Ltd
SSE:600547
|
CN |
|
I
|
Imperium Financial Group Ltd
HKEX:8029
|
HK |
Scidev Ltd
SciDev Ltd. engages in the manufacture and supply of chemicals for industrial wastewater treatment. The company is headquartered in Kings Park, New South Wales. The company went IPO on 2002-05-02. The firm is focused on delivering process control, professional services and chemistry in the mining, construction, water treatment and oil and gas markets. The Company’s products include MaxiFlox and MaxiDry. MaxiFlox and MaxiDry chemistries are designed for a range of applications, including wastewater treatment in construction, mining, mineral processing, oil & gas and water sectors. MaxiFlox and MaxiDry products are supplied in and liquid form, as well as a range of molecular weights, charge distributions and charge densities. The Company’s products also include MaxiFlox organic liquid coagulants, MaxiFlox inorganic liquid coagulant blends, MaxiFlox cationic & anionic flocculant emulsions, MaxiFlox cationic & anionic flocculant powders, MaxiFlox mud solidification polymers, MaxiFlox antifoam products and MaxiDry filter aids.
SciDev Ltd. engages in the manufacture and supply of chemicals for industrial wastewater treatment. The company is headquartered in Kings Park, New South Wales. The company went IPO on 2002-05-02. The firm is focused on delivering process control, professional services and chemistry in the mining, construction, water treatment and oil and gas markets. The Company’s products include MaxiFlox and MaxiDry. MaxiFlox and MaxiDry chemistries are designed for a range of applications, including wastewater treatment in construction, mining, mineral processing, oil & gas and water sectors. MaxiFlox and MaxiDry products are supplied in and liquid form, as well as a range of molecular weights, charge distributions and charge densities. The Company’s products also include MaxiFlox organic liquid coagulants, MaxiFlox inorganic liquid coagulant blends, MaxiFlox cationic & anionic flocculant emulsions, MaxiFlox cationic & anionic flocculant powders, MaxiFlox mud solidification polymers, MaxiFlox antifoam products and MaxiDry filter aids.
Revenue Miss: SciDev's first half revenue and earnings were well below expectations, mainly due to major disruptions with a key Energy Services customer and a sluggish International Water Technologies market.
Guidance Downgrade: FY 2026 revenue guidance was lowered to $100–110 million, reflecting continued delays in xSlik sales, slower conversions in Process Chemistry, and $3 million negative FX impact.
Cost Actions: The company removed up to $3 million in annualized fixed costs and reduced corporate costs by 19% to counteract earnings headwinds.
Recurring Revenue: Recurring revenues now make up 54% of total sales, driven by long-term contracts and O&M agreements, improving earnings visibility.
Business Momentum: Process Chemistry delivered record revenue, APAC Water Technologies returned to profitability, and second quarter results showed signs of recovery with revenue up 9% sequentially.
CatChek Growth: The number of CatChek customers grew 75% year-on-year, diversifying revenue and reducing reliance on single accounts.
Positive Outlook: Management expects second half EBITDA to exceed last year's, citing a strong Q4 exit rate, further cost reductions, and a healthy pipeline heading into FY 2027.
